4.5 Editorial Material

The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 70, Issue 3, Pages 323-325

Publisher

WILEY
DOI: 10.1002/art.40402

Keywords

-

Categories

Funding

  1. AbbVie
  2. Amgen
  3. Bristol-Myers Squibb
  4. Celltrion
  5. GlaxoSmithKline
  6. Novartis
  7. Sanofi Aventis
  8. UCB
  9. Eli Lilly and Company
  10. Pfizer
  11. AstraZeneca
  12. Boehringer Ingelheim
  13. Celgene
  14. Genentech
  15. Janssen
  16. Merck
  17. Roche
  18. Samumed

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available